These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15809363)

  • 21. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.
    Gadzhanova S; Roughead EE; Bartlett LE
    Eur J Clin Pharmacol; 2016 Jun; 72(6):765-71. PubMed ID: 26961086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.
    Linas SL
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S17-23. PubMed ID: 18178792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
    Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.
    Sica DA
    J Clin Hypertens (Greenwich); 2007 Jan; 9(1):78-86. PubMed ID: 17215664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease.
    Baker WL; Coleman CI; Kluger J; Reinhart KM; Talati R; Quercia R; Phung OJ; White CM
    Ann Intern Med; 2009 Dec; 151(12):861-71. PubMed ID: 20008762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?
    Hollenberg NK
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S7-13. PubMed ID: 17401314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term antiproteinuric effect of dual renin-angiotensin system blockade.
    Robles NR; Fernandez Carbonero E; Romero B; Sánchez Casado E; Cubero JJ
    Cardiovasc Ther; 2009; 27(2):101-7. PubMed ID: 19426247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
    Ferrari P
    Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
    Gales BJ; Bailey EK; Reed AN; Gales MA
    Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?
    van den Meiracker AH; Man in 't Veld AJ; Admiraal PJ; Ritsema van Eck HJ; Boomsma F; Derkx FH; Schalekamp MA
    J Hypertens; 1992 Aug; 10(8):803-12. PubMed ID: 1325513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
    Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
    Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What should the physician do when creatinine increases after starting an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker?
    Cohen DL; Townsend RR
    J Clin Hypertens (Greenwich); 2008 Oct; 10(10):803-4. PubMed ID: 19090883
    [No Abstract]   [Full Text] [Related]  

  • 38. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM; van Veldhuisen DJ; van Gilst WH; Voors AA
    Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.